Deciphera Pharmaceuticals (DCPH)
(Delayed Data from NSDQ)
$25.50 USD
+0.02 (0.08%)
Updated May 23, 2024 04:00 PM ET
After-Market: $25.52 +0.02 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Deciphera Pharmaceuticals, Inc. [DCPH]
Reports for Purchase
Showing records 41 - 60 ( 98 total )
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive DCC-3116 and Vimseltinib Data at ESMO Continues Pipeline Momentum; Reit. Buy and Increase PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vimseltinib and DCC-3116 Look to Shine at ESMO Congress 22-Our Previews; Reit Buy and Raising Our PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
DCC-3116 Looks to Target ULK and Investor Interest in Autophagy; Reit Buy and $15PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress Across Pipeline Looks to Create Longer Term Value; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Restructuring Aims To Counter INTRIGUE Failure; Reit. Buy and Lowering Our PT To $15 From $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department